Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Comparative Study
. 2008 Sep;14(9):985-90.
doi: 10.1038/nm.1789. Epub 2007 Jul 31.

"VSports app下载" Circulating mutant DNA to assess tumor dynamics

Frank Diehl  1 , Kerstin Schmidt, Michael A Choti, Katharine Romans, Steven Goodman, Meng Li, Katherine Thornton, Nishant Agrawal, Lori Sokoll, Steve A Szabo, Kenneth W Kinzler, Bert Vogelstein, Luis A Diaz Jr
Affiliations
Comparative Study

"VSports在线直播" Circulating mutant DNA to assess tumor dynamics

Frank Diehl et al. Nat Med. 2008 Sep.

Abstract

The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers for individuals with cancer could similarly enhance the management of their disease VSports手机版. DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. In this study, we applied a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in 162 plasma samples from 18 subjects undergoing multimodality therapy for colorectal cancer. We found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy. We suggest that this personalized genetic approach could be generally applied to individuals with other types of cancer. .

PubMed Disclaimer

Figures

Figure 1
Figure 1. Measurement of ctDNA
The left side of the schematic depicts conventional Sanger sequencing of DNA derived from the subject’s tumor, representing the first step of the analysis. The approach for quantifying tumor-derived DNA in plasma samples is shown on the right. Real-time PCR is used to measure the total number of DNA fragments in the plasma, whereas BEAMing measures the ratio of mutant to wild-type fragments labeled with the fluorescent probes Cy5 and Cy3, respectively.
Figure 2
Figure 2. Representative flow cytometric data obtained from BEAMing
The four graphs illustrate the data obtained from subject 6 (APC G4189T) at different time points during treatment. The green and red dots represent beads bound to wild-type and mutant fragments, respectively. The blue dots represent beads bound to both wild-type and mutant fragments resulting from their inclusion in an emulsion microdroplet that contained both wild-type and mutant DNA templates. Numbers in each quadrant represent events for each population measured. (a) Before surgery, the fraction of mutant DNA fragments was 13.4%. (b) After surgery (day 3), the fraction of mutant DNA fragments dropped to 0.015%. (c) After surgery (day 48), the fraction of mutant DNA fragments increased to 0.11%, suggesting disease recurrence. (d) On day 244, the subject had progressive disease and the fraction mutant DNA fragments increased further to 0.66%.
Figure 3
Figure 3. Recurrence-free survival, as detected by ctDNA and CEA
(a) The difference in recurrence-free survival in subjects with detectable versus undetectable post-operative ctDNA levels (P = 0.006 by Mantel-Cox log-rank test). (b) The difference in recurrence-free survival in subjects with detectable versus undetectable post-operative CEA levels (P = 0.03 by Mantel-Cox log-rank test).
Figure 4
Figure 4. Comparison of ctDNA, CEA and imaging dynamics in individual study subjects
For each subject, the top, middle, and bottom graphs represent ctDNA level, tumor volume as assessed by imaging, and CEA level. The red lines represent the upper bound of the normal levels: one mutant DNA fragment per sample for ctDNA levels, 0.0 cm for tumor diameter, and 5.0 ng ml−1 for CEA abundance. (a) Subject 8 had a sigmoid adenocarcinoma and solitary metastases in both hepatic lobes. The subject underwent a sigmoidectomy and left lateral hepatic sectorectomy (Surgery 1). A right-sided liver metastasis was left in place while the subject was treated with systemic chemotherapy (Chemotherapy 1). On day 120, a right hepatectomy was performed (Surgery 2). After surgery, the subject was treated for 4 months with systemic chemotherapy (Chemotherapy 2). (b) Subject 11 had a sigmoid adenocarcinoma and two liver metastases that were treated with systemic chemotherapy before surgery (Chemotherapy 1). The subject underwent a sigmoid colectomy, left hepatic lobectomy and RFA of a solitary right hepatic lesion (Surgery 1). Imaging studies at 2 months showed recurrence in the liver, and the subject underwent a right hepatectomy (Surgery 2). Given the high risk of recurrence, chemotherapy was reinitiated (Chemotherapy 2). At 8 months, imaging showed three recurrent liver lesions and a suspicious celiac lymph node. The subject underwent RFA of these lesions and resection of the celiac node (Surgery 3). After surgery, the subject received additional chemotherapy (Chemotherapy 3); however, later imaging revealed multiple pulmonary metastases.
See this image and copyright information in PMC

Comment in

References

    1. Wood LD, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–1113. - "V体育2025版" PubMed
    1. Nagrath S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–1239. - PMC - PubMed
    1. Cristofanilli M, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N. Engl. J. Med. 2004;351:781–791. - VSports手机版 - PubMed
    1. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer. 2002;2:210–219. - PubMed
    1. Goebel G, Zitt M, Zitt M, Muller HM. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis. Markers. 2005;21:105–120. - PMC - PubMed

Publication types